Comparative Study of Efficacy and Safety of Sevelamer versus Calcium Acetate in CKD-Related Hyperphosphatemia

1. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019 Oct 1;322(13):1294-1304. doi: 10.1001/jama.2019.14745. 2. Cernaro V, Longhitano E, Casuscelli C, Peritore L, Santoro D. Hyperphosphatemia in Chronic Kidney Disease: The Search for New Treatment Paradigms and the Role of Tenapanor. Int J Nephrol Renovasc Dis. 2024 May 28; 17:151-161. doi: 10.2147/IJNRD.S385826. 3. Raikou VD. Serum phosphate and chronic kidney and cardiovascular disease: Phosphorus potential implications in general population. World J Nephrol. 2021 Sep 25;10(5):76-87. doi: 10.5527/wjn. v10.i5.76. 4. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008 Jul;74(2):148-57. doi: 10.1038/ki.2008.130. 5. Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4. 6. Wang Y, Xie G, Huang Y, Zhang H, Yang B, Mao Z. Calcium acetate or calcium carbonate for hyperphosphatemia of hemodialysis patients: a meta-analysis. PLoS One. 2015 Mar 23;10(3): e0121376. doi: 10.1371/journal.pone.0121376. 7. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 1989 Oct;36(4):690-5. doi: 10.1038/ki.1989.247. 8. Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH; Sevelamer Study Group. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008 Feb;19(2):405-12. doi: 10.1681/ASN.2006101089. 9. Iimori S, Mori Y, Akita W, et al. Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol. 2012 Dec;16(6):930-7. doi: 10.1007/s10157-012-0640-4. 10. Yuste C, Mérida E, Hernández E, García-Santiago A, Rodríguez Y, Muñoz T, Gómez GJ, Sevillano Á, Praga M. Gastrointestinal complications induced by sevelamer crystals. Clin Kidney J. 2017 Aug;10(4):539-544. doi: 10.1093/ckj/sfx013. 11. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. American journal of kidney diseases. 1999 Apr 1;33(4):694-701. DOI: 10.1016/S0272-6386(99)70221-0 12. Hervás JG, Prados D, Cerezo S. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney International. 2003 Jun 1;63: S69-72. DOI: 10.1046/j.1523-1755.63. s85.17.x 13. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney international. 2004 May 1;65(5):1914-26. DOI: 10.1111/j.1523-1755.2004. 00590.x 14. Patel L, Bernard LM, Elder GJ. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clinical Journal of the American Society of Nephrology. 2016 Feb 1;11(2):232-44. DOI: 10.2215/CJN.06800615 15. Habbous S, Przech S, Acedillo R, Sarma S, Garg AX, Martin J. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrology Dialysis Transplantation. 2017 Jan 1;32(1):111-25. DOI: 10.1093/ndt/gfw312 16. Nolan CR, Qunibi WY. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney International. 2005 Jun 1;67: S13-20. DOI: 10.1111/j.1523-1755.2005. 09502.x 17. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. American journal of kidney diseases. 2012 Feb 1;59(2):177-85. DOI: 10.1053/j.ajkd.2011.11.007 18. Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17. PMID: 22607822; PMCID: PMC3437972. 19. Sun PP, Perianayagam MC, Jaber BL. Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism. Kidney Int. 2009 Dec;76(Suppl 114): S20-S25. doi:10.1038/ki.2009.403 20. Yusuf AA, Weinhandl ED, Peter WL. Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D. American journal of kidney diseases. 2014 Jul 1;64(1):95-103. DOI: 10.1053/j.ajkd.2013.11.015